FHTX News & Analysis
2 articles
Market Mood
Foghorn Therapeutics (FHTX) Stock Rating Cut by Wedbush
Wedbush downgraded Foghorn Therapeutics (FHTX) following a setback related to its drug development. The specific reasons for the downgrade were not disclosed in the article. This change in rating could signify potential challenges for the company in meeting market expectations and raise concerns among investors. The announcement highlights the need for investors to stay informed about developments that may affect Foghorn's performance in the market.
Read More: Foghorn Therapeutics (FHTX) Stock Rating Cut by Wedbush
Foghorn Therapeutics (FHTX) Price Target Cut to $5 After Program Halt
H.C. Wainwright has reduced the price target for Foghorn Therapeutics (FHTX) to $5 following a halt in one of its programs. This adjustment reflects concerns over the company's prospects in the market after the program's interruption. The move signals a shift in analyst sentiment, potentially influencing investor confidence and stock performance. For ordinary investors, this means adjusted expectations for Foghorn's stock value, which could impact investment decisions.
Read More: Foghorn Therapeutics (FHTX) Price Target Cut to $5 After Program Halt